#VenObi
LightNews LightNews
vegaversio.bsky.social
Kentress. Venobi.
December 18, 2024 at 10:25 PM
vegaversio.bsky.social
Kentress. Venobi.
August 2, 2024 at 7:00 PM
rarediseaseadvisor.bsky.social
Venetoclax–obinutuzumab (#VenObi) demonstrated durable disease control with partial but steady immune restoration through 48 months. @ash.hematology.org

Read more: https://bit.ly/482ZHOf

#RareDisease #ChronicLymphocyticLeukemia #CLL #Hematology
Sustained CLL Clearance With Ven-Obi Supports Durable Immune Recovery
Fixed-duration venetoclax–obinutuzumab sustained chronic lymphocytic leukemia (CLL) cell depletion while permitting measured immune recovery.
bit.ly
November 28, 2025 at 3:05 PM